Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Huntington, VA
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Huntington, VA
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Norfolk, WV
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Norfolk, WV
Click here to add this to my saved trials
MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer
A Study of Novel Magnetic Resonance Imaging Sequences for Target Delineation and Prognostication in Cervical Cancer
Status: Enrolling
Updated:  5/2/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer
A Study of Novel Magnetic Resonance Imaging Sequences for Target Delineation and Prognostication in Cervical Cancer
Status: Enrolling
Updated: 5/2/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Status: Enrolling
Updated:  5/5/2014
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Status: Enrolling
Updated: 5/5/2014
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Status: Enrolling
Updated:  5/5/2014
Clinical Research Facility
mi
from
Detroit, MI
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Status: Enrolling
Updated: 5/5/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Status: Enrolling
Updated:  5/5/2014
Clinical Research Facility
mi
from
Buffalo, NY
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Status: Enrolling
Updated: 5/5/2014
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Status: Enrolling
Updated:  5/5/2014
Clinical Research Facility
mi
from
San Antonio, TX
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Status: Enrolling
Updated: 5/5/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
Pilot Study to Compare Dynamic MR Imaging Changes in Patients With Recurrent High Grade Glioma, Receiving an Antiangiogenic Drug, Bevacizumab, Versus Dexamethasone. Dual Agent MR Imaging Study, Using Gadolinium and Ferumoxytol (Code 7228)
Status: Enrolling
Updated:  5/12/2014
Oregon Health and Science University
mi
from
Portland, OR
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
Pilot Study to Compare Dynamic MR Imaging Changes in Patients With Recurrent High Grade Glioma, Receiving an Antiangiogenic Drug, Bevacizumab, Versus Dexamethasone. Dual Agent MR Imaging Study, Using Gadolinium and Ferumoxytol (Code 7228)
Status: Enrolling
Updated: 5/12/2014
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Intraoperative Mastectomy Skin Flap Viability During Breast Reconstruction
Status: Enrolling
Updated:  5/12/2014
Stony Brook University
mi
from
Stony Brook, NY
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Intraoperative Mastectomy Skin Flap Viability During Breast Reconstruction
Status: Enrolling
Updated: 5/12/2014
Stony Brook University
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
North Carolina Cancer Hospital at U of North Carolina at CH
mi
from
Chapel Hill, NC
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
North Carolina Cancer Hospital at U of North Carolina at CH
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated:  5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated: 5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Status: Enrolling
Updated:  5/14/2014
Kaiser Permanente Los Angeles (Sunset)
mi
from
Los Angeles, CA
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Status: Enrolling
Updated: 5/14/2014
Kaiser Permanente Los Angeles (Sunset)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Status: Enrolling
Updated:  5/14/2014
Kaiser Permanente Riverside
mi
from
Riverside, CA
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Status: Enrolling
Updated: 5/14/2014
Kaiser Permanente Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
Cancer Research And Biostatistics Clinical Trials Consortium
mi
from
Seattle, WA
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
Cancer Research And Biostatistics Clinical Trials Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
Providence Cancer Center
mi
from
Portland, OR
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
Providence Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
The University of Arizona Cancer Center
mi
from
Tuscon, AZ
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
The University of Arizona Cancer Center
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  5/19/2014
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 5/19/2014
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
Status: Enrolling
Updated:  5/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
Status: Enrolling
Updated: 5/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization
Status: Enrolling
Updated:  5/21/2014
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization
Status: Enrolling
Updated: 5/21/2014
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  5/21/2014
Clinical Research Facility
mi
from
Detroit, MI
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 5/21/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  5/21/2014
Clinical Research Facility
mi
from
New Brunswick, NJ
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 5/21/2014
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  5/21/2014
Clinical Research Facility
mi
from
Dallas, TX
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 5/21/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated:  5/22/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated: 5/22/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated:  5/22/2014
Cotton-O-Neil Cancer Center (Stormont Vail Health Care)
mi
from
Topeka, KA
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated: 5/22/2014
Cotton-O-Neil Cancer Center (Stormont Vail Health Care)
mi
from
Topeka, KA
Click here to add this to my saved trials
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated:  5/22/2014
Truman Medical Center
mi
from
Kansas City, MO
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated: 5/22/2014
Truman Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  5/27/2014
Cancer Therapy & Research Center / UT Health Science Center SC
mi
from
San Antonio, TX
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 5/27/2014
Cancer Therapy & Research Center / UT Health Science Center SC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  5/27/2014
Duke University Medical Center (DUMC)
mi
from
Durham, NC
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 5/27/2014
Duke University Medical Center (DUMC)
mi
from
Durham, NC
Click here to add this to my saved trials
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  5/27/2014
University of California at Los Angeles Dept. of UCLA (4)
mi
from
Los Angeles, CA
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 5/27/2014
University of California at Los Angeles Dept. of UCLA (4)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  5/27/2014
Yale Cancer Center TKI258A2124
mi
from
New Haven, CT
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 5/27/2014
Yale Cancer Center TKI258A2124
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue
Phase I Clinical Trial Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Malignant Colon Tissue
Status: Enrolling
Updated:  5/28/2014
James Graham Brown Cancer Center
mi
from
Louisville, KY
Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue
Phase I Clinical Trial Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Malignant Colon Tissue
Status: Enrolling
Updated: 5/28/2014
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Patient-Centered Acupuncture for Pain (PCAP)
Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors
Status: Enrolling
Updated:  5/30/2014
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Patient-Centered Acupuncture for Pain (PCAP)
Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors
Status: Enrolling
Updated: 5/30/2014
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies
Status: Enrolling
Updated:  6/2/2014
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies
Status: Enrolling
Updated: 6/2/2014
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies
Status: Enrolling
Updated:  6/2/2014
Windber Medical Center
mi
from
Windber, PA
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies
Status: Enrolling
Updated: 6/2/2014
Windber Medical Center
mi
from
Windber, PA
Click here to add this to my saved trials
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients
Status: Enrolling
Updated:  6/2/2014
Walter Reed Army Medical Center
mi
from
Washington,
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients
Status: Enrolling
Updated: 6/2/2014
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients
Status: Enrolling
Updated:  6/2/2014
Windber Medical Center
mi
from
Windber, PA
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients
Status: Enrolling
Updated: 6/2/2014
Windber Medical Center
mi
from
Windber, PA
Click here to add this to my saved trials
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer
Status: Enrolling
Updated:  6/5/2014
University of Virginia
mi
from
Charlottesville, VA
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer
Status: Enrolling
Updated: 6/5/2014
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Benefits of Resistance Exercise Training in Locally Advanced Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Status: Enrolling
Updated:  6/5/2014
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Benefits of Resistance Exercise Training in Locally Advanced Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Status: Enrolling
Updated: 6/5/2014
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Benefits of Resistance Exercise Training in Locally Advanced Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Status: Enrolling
Updated:  6/5/2014
Veterans Affairs (VA) Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Benefits of Resistance Exercise Training in Locally Advanced Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Status: Enrolling
Updated: 6/5/2014
Veterans Affairs (VA) Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
Phase 2 Study of AR-67 (DB-67) in Myelodysplastic Syndrome(MDS)
Status: Enrolling
Updated:  6/23/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
Phase 2 Study of AR-67 (DB-67) in Myelodysplastic Syndrome(MDS)
Status: Enrolling
Updated: 6/23/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Improving Energy Balance in Men With Prostate Cancer
Exploring the Impact of Negative Energy Balance in Men With Prostate Cancer
Status: Enrolling
Updated:  7/7/2014
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Improving Energy Balance in Men With Prostate Cancer
Exploring the Impact of Negative Energy Balance in Men With Prostate Cancer
Status: Enrolling
Updated: 7/7/2014
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Status: Enrolling
Updated:  7/8/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Status: Enrolling
Updated: 7/8/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Status: Enrolling
Updated:  7/8/2014
Karmanos Cancer Institute
mi
from
Detroit, MI
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Status: Enrolling
Updated: 7/8/2014
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Integrative Approaches for Cancer Survivorship
A Whole Systems Approach to the Study of Ayurveda for Cancer Survivorship, Project II
Status: Enrolling
Updated:  7/10/2014
University of California, San Francisco, Osher Center for Integrative Medicine
mi
from
San Francisco, CA
Integrative Approaches for Cancer Survivorship
A Whole Systems Approach to the Study of Ayurveda for Cancer Survivorship, Project II
Status: Enrolling
Updated: 7/10/2014
University of California, San Francisco, Osher Center for Integrative Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials